To include your compound in the COVID-19 Resource Center, submit it here.

Blue Earth reports Phase III data of imaging agent for prostate cancer treatment planning

Blue Earth Diagnostics Ltd. (London, U.K.) said that based on "successful results" of a pre-planned interim analysis, it halted enrollment in the Phase III Falcon trial of

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers